|
1
|
The molecular portraits of breast tumors are conserved across microarray platforms.
|
BMC Genomics
|
2006
|
12.45
|
|
2
|
Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
|
J Clin Oncol
|
2005
|
5.63
|
|
3
|
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
|
J Clin Oncol
|
2006
|
4.84
|
|
4
|
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.
|
Nat Genet
|
2011
|
3.37
|
|
5
|
EGFR associated expression profiles vary with breast tumor subtype.
|
BMC Genomics
|
2007
|
3.35
|
|
6
|
Triple-negative breast cancer: risk factors to potential targets.
|
Clin Cancer Res
|
2008
|
3.25
|
|
7
|
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
|
JAMA
|
2009
|
3.18
|
|
8
|
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2008
|
3.08
|
|
9
|
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.
|
Clin Cancer Res
|
2010
|
3.04
|
|
10
|
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.
|
Cancer Res
|
2005
|
2.73
|
|
11
|
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
|
Clin Breast Cancer
|
2009
|
2.60
|
|
12
|
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.
|
Oncologist
|
2013
|
2.55
|
|
13
|
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
|
J Clin Oncol
|
2011
|
2.47
|
|
14
|
CYP2D6 and tamoxifen: DNA matters in breast cancer.
|
Nat Rev Cancer
|
2009
|
2.32
|
|
15
|
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
|
Clin Cancer Res
|
2013
|
2.09
|
|
16
|
What is triple-negative breast cancer?
|
Eur J Cancer
|
2008
|
2.01
|
|
17
|
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.
|
J Natl Cancer Inst
|
2014
|
1.96
|
|
18
|
A compact VEGF signature associated with distant metastases and poor outcomes.
|
BMC Med
|
2009
|
1.84
|
|
19
|
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
|
Ann Surg Oncol
|
2011
|
1.83
|
|
20
|
Molecular subtypes in breast cancer evaluation and management: divide and conquer.
|
Cancer Invest
|
2008
|
1.80
|
|
21
|
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
|
N Engl J Med
|
2015
|
1.76
|
|
22
|
Understanding and treating triple-negative breast cancer.
|
Oncology (Williston Park)
|
2008
|
1.73
|
|
23
|
Axillary lymph node count is lower after neoadjuvant chemotherapy.
|
Am J Surg
|
2006
|
1.69
|
|
24
|
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.
|
BMC Med Genomics
|
2011
|
1.67
|
|
25
|
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
|
Clin Cancer Res
|
2010
|
1.56
|
|
26
|
Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?
|
J Clin Oncol
|
2010
|
1.55
|
|
27
|
Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research.
|
Oncologist
|
2013
|
1.49
|
|
28
|
Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
|
Ann Surg
|
2002
|
1.47
|
|
29
|
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
|
J Am Coll Surg
|
2009
|
1.46
|
|
30
|
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
|
Breast Cancer Res Treat
|
2012
|
1.43
|
|
31
|
The interaction of post-traumatic growth and post-traumatic stress symptoms in predicting depressive symptoms and quality of life.
|
Psychooncology
|
2008
|
1.37
|
|
32
|
The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
|
Cancer
|
2010
|
1.37
|
|
33
|
Women's experiences with genomic testing for breast cancer recurrence risk.
|
Cancer
|
2010
|
1.29
|
|
34
|
Women's interest in gene expression analysis for breast cancer recurrence risk.
|
J Clin Oncol
|
2007
|
1.27
|
|
35
|
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
|
Breast Cancer Res Treat
|
2012
|
1.23
|
|
36
|
Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
|
Ann Surg Oncol
|
2011
|
1.22
|
|
37
|
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
|
Sci Signal
|
2014
|
1.20
|
|
38
|
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.
|
Cancer Res
|
2014
|
1.19
|
|
39
|
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
|
Breast Cancer Res
|
2009
|
1.19
|
|
40
|
Research issues affecting preoperative systemic therapy for operable breast cancer.
|
J Clin Oncol
|
2008
|
1.18
|
|
41
|
Gene expression profiling in breast cancer.
|
Curr Opin Oncol
|
2007
|
1.15
|
|
42
|
Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy.
|
J Natl Compr Canc Netw
|
2008
|
1.12
|
|
43
|
Molecular profiling in breast cancer.
|
Rev Endocr Metab Disord
|
2007
|
1.10
|
|
44
|
Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.08
|
|
45
|
Knowledge of genomic testing among early-stage breast cancer patients.
|
Psychooncology
|
2011
|
1.08
|
|
46
|
Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.
|
Mol Cancer Res
|
2010
|
1.07
|
|
47
|
Quantifying the recruitment challenges with couple-based interventions for cancer: applications to early-stage breast cancer.
|
Psychooncology
|
2009
|
1.06
|
|
48
|
Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.
|
Clin Cancer Res
|
2007
|
1.04
|
|
49
|
Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients.
|
Breast Cancer Res
|
2012
|
1.03
|
|
50
|
Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
|
Semin Radiat Oncol
|
2009
|
0.99
|
|
51
|
Improving communication of breast cancer recurrence risk.
|
Breast Cancer Res Treat
|
2011
|
0.98
|
|
52
|
When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.
|
Breast Cancer Res Treat
|
2008
|
0.97
|
|
53
|
PARP and cancer--if it's broke, don't fix it.
|
N Engl J Med
|
2011
|
0.96
|
|
54
|
Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer.
|
Mol Carcinog
|
2008
|
0.96
|
|
55
|
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
|
Cancer Chemother Pharmacol
|
2008
|
0.94
|
|
56
|
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.
|
Breast Cancer Res
|
2011
|
0.93
|
|
57
|
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
|
Clin Breast Cancer
|
2006
|
0.93
|
|
58
|
Clonal evolution of lymphoblastoid cell lines.
|
Lab Invest
|
2006
|
0.93
|
|
59
|
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.92
|
|
60
|
Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer.
|
Oncol Rep
|
2008
|
0.92
|
|
61
|
Clinical trials in triple negative breast cancer.
|
Breast Dis
|
2010
|
0.92
|
|
62
|
The management of early-stage and metastatic triple-negative breast cancer: a review.
|
Hematol Oncol Clin North Am
|
2013
|
0.92
|
|
63
|
Improving endocrine therapy for breast cancer: it's not that simple.
|
J Clin Oncol
|
2012
|
0.91
|
|
64
|
Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer.
|
J Clin Oncol
|
2009
|
0.91
|
|
65
|
Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study.
|
Radiology
|
2007
|
0.91
|
|
66
|
Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic.
|
Ann Surg Oncol
|
2006
|
0.90
|
|
67
|
Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer.
|
Med Image Comput Comput Assist Interv
|
2006
|
0.90
|
|
68
|
Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.
|
Breast Cancer Res Treat
|
2015
|
0.89
|
|
69
|
Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.
|
Breast Cancer Res Treat
|
2015
|
0.88
|
|
70
|
Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.
|
Breast Cancer Res
|
2007
|
0.88
|
|
71
|
Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer.
|
Cancer Immunol Immunother
|
2004
|
0.87
|
|
72
|
Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk.
|
Carcinogenesis
|
2006
|
0.87
|
|
73
|
Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
|
Exp Mol Pathol
|
2013
|
0.86
|
|
74
|
The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer.
|
Ann Surg Oncol
|
2014
|
0.86
|
|
75
|
Understanding how breast cancer patients use risk information from genomic tests.
|
J Behav Med
|
2012
|
0.86
|
|
76
|
Gene-expression analysis and the basal-like breast cancer subtype.
|
Future Oncol
|
2007
|
0.85
|
|
77
|
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
|
Clin Breast Cancer
|
2010
|
0.83
|
|
78
|
Defining the expressed breast cancer kinome.
|
Cell Res
|
2012
|
0.82
|
|
79
|
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
|
Breast Cancer Res Treat
|
2014
|
0.82
|
|
80
|
Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers.
|
Am J Surg
|
2005
|
0.81
|
|
81
|
Engaging in health behaviors to lower risk for breast cancer recurrence.
|
PLoS One
|
2013
|
0.81
|
|
82
|
Current treatment paradigms for the management of patients with brain metastases.
|
Neurosurgery
|
2005
|
0.81
|
|
83
|
Reporting of race and ethnicity in breast cancer research: room for improvement.
|
Breast Cancer Res Treat
|
2009
|
0.80
|
|
84
|
Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate.
|
Am Surg
|
2011
|
0.79
|
|
85
|
Breast cancer: HER2--a good addiction.
|
Nat Rev Clin Oncol
|
2012
|
0.78
|
|
86
|
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
|
Breast Cancer Res Treat
|
2014
|
0.78
|
|
87
|
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
|
Breast Cancer Res Treat
|
2015
|
0.78
|
|
88
|
Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.
|
Oncologist
|
2012
|
0.78
|
|
89
|
Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
|
Oncology (Williston Park)
|
2006
|
0.77
|
|
90
|
Neoadjuvant trials of human epidermal growth factor receptor 2 targeting: how many drugs do we need?
|
J Clin Oncol
|
2012
|
0.76
|
|
91
|
The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
|
J Biopharm Stat
|
2015
|
0.76
|
|
92
|
High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
|
Am J Surg
|
2004
|
0.76
|
|
93
|
Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases.
|
PLoS Med
|
2017
|
0.75
|
|
94
|
Adjuvant systemic therapy in young women.
|
Breast Dis
|
2006
|
0.75
|
|
95
|
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.
|
Pharmacogenet Genomics
|
2017
|
0.75
|